Invest Smart, Grow Fast! Industries with Up to 20% Annual Growth
"Discover High-Growth Opportunities Across Leading Sectors, With BCC Research Highlighting Industries Primed for Up to 20% Annual Returns" BOSTON, Oct....
Vaccine
Tonix Pharmaceuticals to Present at BIO-Europe® 2024
CHATHAM, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated...
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth –– ARCALYST 2024 expected net...
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability
Preliminary Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with approximately $107 million in...
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
Following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical trial participants were...
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company...
Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv
Oslo, October 25, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that...
Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference
CHATHAM, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated...
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance...
Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting
Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ PlatformREDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE)...
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025
Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27%Operating cash flow of $326 million Note: A webcast of...
Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024
HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents...
Moderna Named a Top Employer by Science for Tenth Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top...
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024
CHATHAM, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage...
Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present...
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company...
BuzzRx® Introduces Vaccination Scheduling Functionality
Tool Helps Customers Find and Schedule Vaccine Appointments at CVS Pharmacy FORT LAUDERDALE, Fla., Oct. 22, 2024 /PRNewswire/ -- BuzzRx, a free...
Dotmatics Introduces Luma Antibody & Protein Engineering Solution for End-to-End Antibody Discovery
The first in a series of Dotmatics Luma Multimodal R&D Solutions Geneious has been seamlessly composed into Luma showcasing cross-therapeutic...
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine
Study to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute...
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif.,...